Barrett esophagus and who have undergone antireflux surgery, a substantial minority of patients develop acid reflux again. 2, 3 Furthermore, this recurrence of reflux is not always symptomatic. 4 It is therefore possible that providing surgery stops reflux over the long term; it may prevent progression of Barrett's mucosa to cancer. If this was found to be so, then 24-hour pH surveillance following antireflux surgery would be much more important than is currently regarded to be the case.
However, the study by Chang et al contains a finding that raises another and rather more fundamental doubt regarding the problem of Barrett esophagus. Is it possible that Barrett esophagus has nothing particularly to do with esophageal cancer at all? The problem with Barrett esophagus being seen as an independent factor in the development of cancer of the esophagus is the near impossibility of separating it from the reflux that causes it in the first place. Best current evidence tells us that there is an association between reflux and adenocarcinoma, and this association is strong in patients with severe symptoms of reflux over a long period. 5 It also tells us that patients who develop Barrett esophagus are at the worst end of the reflux spectrum. 6, 7 Now consider the following: 9 and yet the ratio for adenocarcinoma of the esophagus is more like 10:1. 10 3. In any surgical series of esophagectomy for adenocarcinoma, the incidence of demonstrated Barrett's mucosa is only of the order of half of the patients. 11, 12 This is usually dismissed as being because the metaplastic mucosa has been replaced by cancer. However, it is equally possible that there was no metaplastic mucosa in the esophagus in the first place. 4. It was once thought that the longer the segment of Barrett's mucosa, the greater the risk for the development of adenocarcinoma. Strong doubt was raised about this association, however. 13 
Now the paper by Chang et al shows that significant
regression of columnar-lined esophagus occurred in the surgical group compared with the medical group of patients, without significantly changing the incidence of cancer.
It is possible that adenocarcinomas do not arise from columnar cells but from some form of stem cell, and so perhaps the true proximate cause of the cancer is not Barrett's mucosa at all, but chronic inflammation, a time-honored pathogenetic factor for cancer. Reflux is an important cause for such inflammation but may not explain the steep rise in incidence of cancer in the past 30 years. It is certainly easier to explain the 5 points above if there is some other factor at work that has yet to be identified. And so, in the spirit that I think Richard Feynman would approve, the question needs to be asked: "Is Barrett's mucosa really so important in the development of adenocarcinoma, other than as a marker of severe reflux disease?" and does our persistent concentration on it divert our attention from finding an as yet unidentified, but much more important, cause of adenocarcinoma involving the esophagus?
